Daily statin use safely cuts the risk of a first major heart attack or stroke by 30 percent in healthy adults aged 70 and over, according to a landmark clinical trial led by Monash University researchers and published on August 29, 2026, in the New England Journal of Medicine.
A decade-long clinical trial has delivered a definitive answer to a long-standing question in primary care: prescribing a daily cholesterol-lowering medication to healthy older adults significantly reduces cardiovascular emergencies without imposing a heavy toll of serious side effects. The study, known as the Statins in Reducing Events in the Elderly (STAREE) trial, monitored almost 10,000 participants over the age of 70 who were enrolled with the help of nearly 3,400 general practitioners across Australia, as The Guardian reported.
While statins have long been standard preventative care for younger individuals or patients with pre-existing heart disease, older populations were historically overlooked in early clinical trials. Researchers excluded individuals who were not living independently, those who already required statins following a previous cardiac event, or patients with conditions that made the medication unsafe.
Trial Findings and the Real-World Impact on Older Adults
The cohort had a mean age of 74.7 years, and 52 percent were women. Over a median follow-up of 5.9 years, major cardiovascular events occurred in 6.0 percent of those assigned the statin, compared with 8.3 percent of those assigned the placebo.
That absolute difference of 2.3 percentage points translates to a 30 percent relative reduction in first major cardiac events, such as a heart attack, stroke, coronary revascularisation, or cardiovascular death.
“The risk of heart attack and stroke remains a major concern for older people, and that having solid evidence for a safe, effective way to reduce that risk will offer real reassurance to older Australians and their families.”
Professor Sophia Zoungas, Lead Researcher
The results were presented concurrently at the European Society of Cardiology Congress in Germany. UA.News highlighted that the study addresses an aging global society where the absolute burden of disease grows alongside life expectancy.
Debunking Dementia Fears and Weighing Limitations
For years, persistent misinformation suggested that statin therapy increased the risk of dementia, causing many elderly patients to reject or discontinue the drugs. The STAREE trial provides robust evidence to put those concerns to rest. Researchers found no statistically significant difference in dementia rates between the participants who received the daily statin and those who received the placebo.
However, the trial also uncovered clear boundaries regarding what statins can achieve. While cardiovascular events dropped sharply, the secondary co-primary endpoint—disability-free survival, defined as living without dementia or persistent physical disability—showed no significant difference between the two groups, with 12.8 percent of the statin group and 13.6 percent of the placebo group reaching that endpoint.
Adherence also presented a hurdle in primary care. Furthermore, cardiologists pointed out that the trial cohort was almost exclusively white, meaning that clinicians must exercise caution when generalizing the findings globally without supporting data from diverse populations.
Future Guidelines and Clinical Recommendations
In response to the data, the National Heart Foundation of Australia is preparing to release updated clinical guidelines within the next six months to assist general practitioners in managing older patients. Professor Derek Chew, chief scientist and medical officer at the National Heart Foundation, emphasized that for patients over 70, medical care is increasingly focused on preserving independence and avoiding debilitating hospitalizations.
Researchers advise older adults and their families to consult their general practitioners to discuss individual five-year cardiovascular risks and determine whether introducing a statin aligns with their personal health goals. With treatment guidelines expected to evolve, the medical community now possesses robust trial data to guide preventative care for an aging population.
Keep reading
- Carotid Endarterectomy Patch Materials: Synthetic vs Biological Patches – A Systematic Review of Stroke and Complication Risks
- EU Corona Aid to Cost German Taxpayers 150 Billion Euros Over Next Decades
- Cholesterol Medication Cuts Cardiovascular Risk by 30% in Healthy Older Adults (newsdirectory3.com)
- Atorvastatin Cuts Heart Attack and Stroke Risk 30% in Older Adults (time.news)
